OrthoFX™, a leader in innovative clear aligner technology, announced preliminary results from a retrospective clinical study comparing treatment effectiveness and predictability of its FXClear aligner system with the leading clear aligner brand, Invisalign. The study, titled "Treatment Effectiveness of FXClear Aligner.
Kivu Bioscience, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers, announced the appointment of Mohit Trikha, Ph.D., as Chief Executive Officer. Dr. Trikha, who previously served as President and Chief Operating Officer, assumes the role following the company’s continued progress advancing its pipeline programs ahead of schedule.
Dexcel Pharma USA is pleased to announce that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nintedanib Capsules, 100 mg and 150 mg, the generic equivalent of OFEV® (nintedanib) capsules1. Nintedanib is indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a serious and progressive lung disease.
Johnson & Johnson a worldwide leader in multiple myeloma therapies, announced that the U.S. Food and Drug Administration (FDA) approved TECVAYLI® plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.1 TECVAYLI® and DARZALEX FASPRO® work synergistically to prime and activate the immune system to eradicate myeloma cells that express the BCMA protein.
BD a leading global medical technology company, announced it has obtained CE Marking for the Revello™ Vascular Covered Stent, a next-generation endovascular solution for the treatment of atherosclerotic lesions in the common and external iliac arteries.
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced the launch of Diphenhydramine Hydrochloride Injection, USP in the United States.
Otsuka Medical Devices Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. (Otsuka Pharmaceutical) announce that the Paradise™ Ultrasound Renal Denervation (uRDN) system is covered by National Health Insurance system in Japan, effective March 1. Following the inception of insurance coverage, Otsuka Medical Devices has commenced sales of the system on March 2 and will conduct co-promotion with Otsuka Pharmaceutical.
Vetter, one of the world's leading pharmaceutical service providers for the production of injectable drugs, has confirmed its plans to build a state-of-the-art production facility in the Saarland region of southwest Germany.
Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced a first commercial engagement with a medical center in the United States, following receipt of FDA approval for its home pregnancy ultrasound product.
Zinc Saves Kids, a global child‑health initiative of the International Zinc Association (IZA), has announced a new partnership with leading Zambian pharmaceutical manufacturer Pharmanova Zambia Limited to expand access to life‑saving zinc treatments for children across Zambia.